HIT Consultant July 2, 2024
What You Should Know:
– Eli Lilly’s Kisunla™ (donanemab-azbt) has been approved by the FDA as a treatment for adults in the early stages of Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI) and mild dementia, who have confirmed amyloid plaque buildup in the brain.
– The FDA approval marks a significant step forward in the fight against Alzheimer’s, offering new hope for patients and their families.
How Kisunla Works
Kisunla targets amyloid plaques, protein clumps associated with Alzheimer’s progression. By helping the body remove these plaques, Kisunla may slow the decline in memory, thinking, and daily activities experienced by Alzheimer’s patients.
Clinical Trial Results
Studies showed promising results, particularly for patients in the early stages...
Today's Sponsors
Today's Sponsor